CALGB 9633: an underpowered trial with a methodologically questionable conclusion.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

8 citing papers in PubMed.

1. genRCT: a statistical analysis framework for generalizing RCT findings to real-world population.Journal of biopharmaceutical statistics · 2024
   Article
2. Elastic integrative analysis of randomised trial and real-world data for treatment heterogeneity estimation.Journal of the Royal Statistical Society. Series B, Statistical methodology · 2023
   Article
3. Deconstructing ADAURA: It is Time to Forgo Adjuvant Platinum-Based Chemotherapy in Resected IB-IIIALung Cancer (Auckland, N.Z.) · 2022
   Article
4. RWD-INTEGRATED RANDOMIZED CLINICAL TRIAL ANALYSIS.Biopharmaceutical report · 2022
   Article
5. Neoadjuvant versus adjuvant chemotherapy for resectable non-small cell lung cancer debate revisited.Journal of thoracic disease · 2019
   Article
6. Adjuvant Chemotherapy After Lobectomy for T1-2N0 Non-Small Cell Lung Cancer: Are the Guidelines Supported?Journal of the National Comprehensive Cancer Network : JNCCN · 2015
   Article
7. Validation of a molecular and pathological model for five-year mortality risk in patients with early stage lung adenocarcinoma.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2015
   Article
8. MicroRNA-31 predicts the presence of lymph node metastases and survival in patients with lung adenocarcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2013
   Article

Corrections and comments

• Comment on
  Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups.2008

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as